Brainsway Company Insiders
| BWAY Stock | USD 23.04 1.15 4.75% |
Brainsway employs about 120 people. The company is managed by 19 executives with a total tenure of roughly 280 years, averaging almost 14.0 years of service per executive, having 6.32 employees per reported executive. Break down of Brainsway's management performance can provide insight into the company performance.
Brainsway | Build AI portfolio with Brainsway Stock |
Brainsway Management Team Effectiveness
The company has return on total asset (ROA) of 0.0192 % which means that it generated a profit of $0.0192 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.1095 %, meaning that it created $0.1095 on every $100 dollars invested by stockholders. Brainsway's management efficiency ratios could be used to measure how well Brainsway manages its routine affairs as well as how well it operates its assets and liabilities.Brainsway holds a total of 19.59 Million outstanding shares. 30% of Brainsway outstanding shares are owned by other corporate entities. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Some institutional investors establish a significant position in stocks such as Brainsway in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of Brainsway, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.
Brainsway Workforce Comparison
Brainsway is rated below average in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 4,739. Brainsway holds roughly 120 in number of employees claiming about 2.53% of equities under Health Care industry.
The company has Profit Margin (PM) of 0.13 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.09 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.09. Brainsway Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Brainsway Price Series Summation is a cross summation of Brainsway price series and its benchmark/peer.
Brainsway Notable Stakeholders
A Brainsway stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Brainsway often face trade-offs trying to please all of them. Brainsway's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Brainsway's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| David MD | CoFounder ViceChairman | Profile | |
| Menachem Esq | General VP | Profile | |
| Christopher Jako | Pres CEO | Profile | |
| Ido Marom | Chief Officer | Profile | |
| Colleen Hanlon | Vice Affairs | Profile | |
| Gilead Moiseyev | Chief Officer | Profile | |
| Moria Ankri | VP RD | Profile | |
| Dor Hagai | Vice Operations | Profile | |
| Pr Zangen | Member CoFounder | Profile | |
| Hillegonda Groen | Vice Sales | Profile | |
| Ross Mitchell | Vice Marketing | Profile | |
| Richard MD | Chief Officer | Profile | |
| Avner Hagai | Founder ViceChairman | Profile | |
| Christopher Boyer | Vice Marketing | Profile | |
| Hadar Levy | Chief Officer | Profile | |
| Yiftach Roth | Chief Scientist | Profile | |
| Aron Tendler | Chief Officer | Profile | |
| Richard Areglado | VP CFO | Profile | |
| Michael Cohen | Vice Sales | Profile |
About Brainsway Management Performance
The success or failure of an entity such as Brainsway often depends on how effective the management is. Brainsway management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Brainsway management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Brainsway management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Brainsway Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States, Europe, Israel, and internationally. Brainsway Ltd. was founded in 2003 and is headquartered in Jerusalem, Israel. Brainsway operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 118 people.
Please note, the imprecision that can be found in Brainsway's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Brainsway. Check Brainsway's Beneish M Score to see the likelihood of Brainsway's management manipulating its earnings.
Brainsway Workforce Analysis
Traditionally, organizations such as Brainsway use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Brainsway within its industry.Brainsway Manpower Efficiency
Return on Brainsway Manpower
| Revenue Per Employee | 341.8K | |
| Revenue Per Executive | 2.2M | |
| Net Income Per Employee | 24.3K | |
| Net Income Per Executive | 153.7K | |
| Working Capital Per Employee | 536K | |
| Working Capital Per Executive | 3.4M |
Additional Tools for Brainsway Stock Analysis
When running Brainsway's price analysis, check to measure Brainsway's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Brainsway is operating at the current time. Most of Brainsway's value examination focuses on studying past and present price action to predict the probability of Brainsway's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Brainsway's price. Additionally, you may evaluate how the addition of Brainsway to your portfolios can decrease your overall portfolio volatility.